Tags : Bayer

Bayer Acquires Asklepios for ~$4B

Shots: Bayer acquires AskBio for $2B as upfront and ~2B as milestones with 75% of the milestones to be paid during the next five years. The transaction is expected to be close in Q4’20 The focus of the acquisition is to foster Bayer’s cell and gene therapy platform with the potential to bring treatments to […]Read More

PharmaShots Weekly Snapshot (Oct 19 – 23, 2020)

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week Published: Oct 23, 2020 | Tags: Akebia, Results, Vadadustat, P-lll, INNO2VATE Global Study, Anemia, Chronic Kidney Disease Sanifit Presents Results of SNF472 for the Treatment of Vascular Calcification at ASN Kidney Week 2020 Published: Oct 22, 2020 […]Read More

Bayer and 111 Collaborate to Explore the Vast Blue Ocean

Shots: The companies will collaborate on drug commercialization initiatives in China, including the commercialization of innovative drugs & healthcare products for chronic disease management, as well as providing reliable and convenient resources for patient education Bayer will leverage 111’s vast network of pharmacies and healthcare providers to enhance its channel management and patient outreach capabilities, […]Read More

PharmaShots Weekly Snapshot (Oct 12-16, 2020)

Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, Luxturna, Novartis, receives, voretigene neparvovec Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis Published: Oct 15, […]Read More

Bayer Report Results of Aliqopa (copanlisib) + Rituximab in P-III

Shots: The P-III CHRONOS-3 study involves assessing of Aliqopa + rituximab vs PBO + rituximab in 458 patients with relapsed indolent NHL who have received at least one or more lines of prior rituximab-containing treatment The P-II study met its 1EP of prolonged PFS, safety is consistent with previously published data on the individual components […]Read More

Top 20 Oncology Companies by Total Products

To remain successful in the oncology market, change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However, despite robust levels of pipeline activity, oncology remains a challenging area for research […]Read More

Insights+: The US FDA New Drug Approvals in August 2020

The US FDA has approved multiple NDAs and BLAs in Aug 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 69 novel products so far in 2020, including 10 in Aug 2020. Additionally, […]Read More

Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for

Shots: Recursion to receive $30M as up front, $50M as equity investment, ~$100M/ program as development and commercial milestones along with royalties on sales. The companies will work on more than ten programs Bayer will get an exclusive option to license novel therapies derived from the research activities The collaboration will deploy Recursion’s AI-guided drug […]Read More

PharmaShots Weekly Snapshot (Aug 24 -28, 2020)

1. Taysha Gene Therapies’ TSHA-101 Receives the US FDA’s Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis Published: Aug 27, 2020 | Tags:  Taysha Gene Therapies, TSHA-101, Receives, US, FDA, Orphan Drug Designation, Rare Pediatric Disease Designation, GM2 Gangliosidosis 2. Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic […]Read More

Bayer Reports the NDA Submission to NMPA for Vericiguat to

Shots: The NDA submission was submitted to NMPA’s CDE and is based on P-III VICTORIA study, seeking regulatory approval of vericiguat in China In Oct’2014, Bayer and MSD signed a WW agreement for sGC modulators. The therapy is being jointly developed by both the companies as per the collaboration and has received the US FDA’s […]Read More